United Statesir.formatherapeutics.com
Forma Therapeutics Holdings, Inc., commonly known as Forma Therapeutics, is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts. Founded in 2007, it specializes in the discovery, development, and commercialization of novel therapeutics for rare hematologic diseases such as sickle cell disease (SCD) and thalassemia, as well as certain cancers.
The company's proprietary drug discovery platform integrates advanced biology insights with chemistry expertise to target challenging pathways, including protein-protein interactions, epigenetics, and tumor metabolism. Its lead candidate, etavopivat (formerly FT-4202), is an oral, once-daily activator of red blood cell pyruvate kinase (PKR). By lowering 2,3-DPG levels and increasing ATP, etavopivat aims to enhance hemoglobin-oxygen affinity, reduce sickle hemoglobin polymerization, and improve red blood cell integrity.
In 2022, Novo Nordisk acquired Forma Therapeutics for $1.1 billion, integrating it as a subsidiary to bolster its pipeline in hemoglobinopathies. Etavopivat has shown promising phase 3 results from the HIBISCUS trial, including reduced vaso-occlusive crises and hemoglobin increases, with regulatory submission planned for late 2026.
Also known as Forma Therapeutics, Inc..
None yet. When a new project in the record names Forma Therapeutics as owner, partner or investor, it shows here.
HIBISCUS phase‑3 (n=385, ≥12 yrs): etavopivat cut VOCs by 27% and delayed first VOC ~4 months; 48.7% had >1 g/dL Hb rise at 24 weeks vs 7.2% placebo. Well tolerated; filing H2 2026.
